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Combined syndromeAbstract Continuous positive airway pressure (CPAP) is a standard treatment of moderate and
severe obstructive sleep apnea syndrome. However, its effect in patients with coexisting obstructive
and central apneas is controversial.
Objectives: To determine the immediate response to CPAP in combined obstructive and central
sleep apnea patients without heart failure.
Methods: Thirty seven consecutive patients with moderate and severe coexisting obstructive and
central apneas (combined group) were prospectively enrolled in this cross sectional analytic study.
All patients underwent a full night-attended and a full night CPAP titration polysomnography.
Titration was considered successful if AHI < 10 and the titration study included at least 15 min
in REM stage.
Results: On CPAP titration, the combined group showed signiﬁcant improvement in sleep
and respiratory polysomnographic parameters. Mean AHI was reduced from 71.9 ± 30.3 to
8.39 ± 5.15 (P= 0.000). Whereas CPAP signiﬁcantly reduced the central apnea index from
12.8 ± 6.67 to 3.1 ± 2.86 (P= 0.000), the response to central events was variable (ranged from
20% to 100%). Overall results, 25 (67.6%) had successful titration with signiﬁcant better response
in females than males to CPAP than males (88.9% vs. 60.7%, P= 0.019).
Conclusion: CPAP can be effective in combined obstructive and central apnea patients without
heart failure with consideration of individual variability. A trial of CPAP titration should be done
in those patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
674Introduction
Sleep related breathing disorders (SRBD) have been recently
classiﬁed into obstructive sleep apnea syndrome (OSAS), the
central sleep apnea syndrome (CSAS) and Cheyne–Stokes
respiration (CSR) [1]. Due to overlap of mechanisms of upper
airway obstruction and ventilatory instability causing these
disturbances, one patient could present with combination of
obstructive and central events in one night. This condition is
commonly present in patients with congestive heart failure
but can interestingly occur without heart failure [2].
Continuous positive airway pressure (CPAP) acts as a
pneumatic splint to the upper airway during sleep and corrects
the obstruction. It therefore can improve oxygenation and
sleep architecture [3]. While the treatment of obstructive sleep
apnea syndrome is generally straight forward and successful
with CPAP therapy, [4] treatment of sleep apnea with predom-
inantly mixed apneas, CSA and CSR is not universally agreed
upon. CSA occurring with episodes of obstructive or mixed
apnea may respond to nasal CPAP therapy [5–7]. One possible
explanation is that CPAP increases lung volume and oxygen
stores and alleviates hypoxia. Also, it prevents the occurrence
of upper airway narrowing or occlusion during central apnea
resulting in decreasing ventilatory overshoot and stabilization
of ventilation [8]. Other reports have demonstrated either no
change or a worsening of apnea/hypopnea index (AHI) during
acute administration of nasal CPAP [9,10]. Depending on
these results, a trial of CPAP may be effective in treatment
of patients with coexisting obstructive and central sleep apnea.
Aim of the study
To determine the immediate effect of CPAP on elimination of
apneas, improvement of oxygenation and sleep architecture in





We included adult patients with coexisting obstructive and
central sleep disordered breathing (combined group) (diag-
nosed by polysomnography as total AHIP 15 and central
AHIP 5 and the central AHI < 50% of total AHI).
To be eligible for enrollment in the study, patients should
undergo full night diagnostic and full night CPAP titration
polysomnographic study.
Exclusion criteria
 Patients with pure OSAS.
 Patients associated with other pulmonary diseases as
COPD, asthma, interstitial lung disease, bronchiectasis etc.
 Patients with left-sided heart failure.
 Patients who developed claustrophobia or excessive mask
leak (leak > 0.04 L/s > 20% of total sleep time) during
CPAP titration.
 Patients with split night sleep study.Study designThis cross-sectional analytic study was carried at the sleep lab-
oratory of the Chest Department of Assiut University Hospi-
tal. An informed written consent was obtained from all the
patients enrolled in the study. The study was approved by
the Faculty of Medicine Ethics Committee, Assiut University.
Over a period of one and half years, we assessed patients
coming for full night polysomnography. Patients with moder-
ate to severe combined sleep apnea were prospectively enrolled
in the study and prepared for second full night attended CPAP
titration sleep study.
Clinical assessment
Clinical history suggestive of sleep apnea syndrome was taken
from the patients and their partner with a history of associated
co-morbid disease as diabetes mellitus, hypertension or IHD.
Physical assessment including anthropometric measurement
of height, weight and body-mass index (BMI) and reviewing
of patients pulmonary function tests, previous chest X-ray
and echocardiography was carried out.
Polysomnography
All patients underwent full over-night attended diagnostic as
well as therapeutic (on CPAP) polysomnography (Sleep Lab
Pro, Jaeger, VIASYS Healthcare Hoechberg, Germany). On
both the two nights, the polysomnogram systematically
monitored electroencephalogram (EEG) (C3-A2, C4-A1),
electro-oculogram (EOG), electromyogram of the chin
(EMG), electrocardiogram (EKG), nasal and oral airﬂow
(using oronasal ﬂow thermistor in the diagnostic study and a
piezoelectric pressure sensor to record mask pressure in the
therapeutic study), thoracic and abdominal effort (using
piezoelectric belts), limb movements (by means of EMG on
anterior tibialis muscle), pulse oximetry, body position
(recorded by a position sensor) and snoring sound level (by
means of a microphone placed externally to the trachea).
S. Farghaly, A. ThabetCPAP titration
CPAP therapy was introduced with full night attended
polysomnography within 3 weeks after the diagnostic study.
All patients received CPAP via an oronasal mask which was
selected individually. The auto mode of CPAP device
(Resmed, Autoset spiritTM) with a pressure range of 4–20 cm
H2O was used for automatic titration. It automatically
increased or decreased mask pressure in response to snoring
or the presence of apneas or hypopneas, thus acting to com-
pletely restore airway patency. It detected degree of obstruc-
tion by reviewing the shape of the inspiratory ﬂow curve on
a breath-by-breath basis. A normal unobstructed breath gives
a smooth rounded curve shape, but, as the upper airway nar-
rows, ﬂattening of the curve occurs, altering the shape. The
degree of ﬂattening determines the response of the device
[11]. Preparation of the patients was done by a technician
who supervised the study, and adjusted the mask ﬁt to com-
pensate for leak and patient discomfort.
Table 1 Demographic data of the study group.
Variable (N= 37)






BMI (mean ± SD) 40.21 ± 8.022
Comorbidities (%)
Hypertension 23 (62.2%)
Diabetes mellitus 14 (37.8%)
Ischemic heart disease 14 (37.8%)
Data expressed as number (%) or mean ± SD (standard
deviation).
BMI, body mass index.
Figure 1 The response of obstructive apnea index (OAI) to
CPAP in patients with combined sleep apnea syndrome. CPAP
signiﬁcantly reduced the OAI from 29.50 ± 22.30 to 4.86 ± 3.6
(P= 0.000). The degree of response varies from 60% to 100%.
Role of continuous positive airway pressure in sleep apnea syndrome 675Polysomnography scoring
The polysomnograms were scored automatically and revised
manually according to American academy of sleep medicine
[12]. Apnea was deﬁned as a complete cessation of airﬂow
for more than 10 s. Obstructive apnea was an apnea with pre-
served respiratory effort. Central apnea is an apnea with
absent respiratory effort. Hypopnea required an event of at
least 10 s duration in association with a P30% drop in the
baseline amplitude and aP4% desaturation from the baseline
saturation. The AHI was calculated as the number of apnea
and hypopnea events per hour of sleep. Desaturation was
detected by drop of at least 4% below baseline. An arousal
was deﬁned as an abrupt change in the EEG frequency to
alpha, theta, or faster frequency in non-rapid eye movement
(NREM) sleep with an increase in submental EMG as well
in rapid eye movement (REM) lasting at least 3 s [13].
After manual scoring of the different previous variables, a
polysomnographic report was printed including data of sleep
[total seep time (TST), sleep efﬁciency, sleep stages%], respira-
tory [total, NREM and REM AHI, obstructive and central
events and oxygen indices (desaturation index (DI), average
oxygen level, minimum oxygen level, time spent below 90%
(T90)] and cardiovascular [slowest and fastest heart rate]
parameters. In the report of the second night, data about dif-
ferent CPAP pressures applied during the study were detected.
Titration was considered successful if overall results showed
AHI < 5 and the study included at least 15 min in REM stage.
Statistical analysis
Statistical Package for the Social Sciences (SPSS-version 16)
software was used for analysis of results. Results in this study
were presented in mean ± standard deviation or number and
percentage. The qualitative data were compared between the
successful and non successful group using chi-square test.
Paired sample student t-test was used to analyze quantitative
polysomnographic data on CPAP compared to baseline. The
difference was considered signiﬁcant when P< 0.05.
Results
We included 37 with coexisting obstructive and central sleep
apnea (combined group) for analysis. We excluded 62 patients
with pure OSAS, 30 patients with associated pulmonary dis-
eases and 9 patients with excessive leak during CPAP titration.
The combined group was 67.6% male with a mean age of
51.22 ± 8.9. They were obese with mean BMI 40.21
± 8.022. The demographic data are shown in Table 1.
On CPAP titration, the combined group showed a signiﬁ-
cant improvement in most polysomnographic variables. Sleep
efﬁciency was signiﬁcantly increased. Light sleep (stage 1 and
stage 2) % of TST was signiﬁcantly decreased with a signiﬁ-
cant increase in % of both of deep (i.e. stage 3) and REM
sleep. Furthermore, CPAP signiﬁcantly reduced all apneas
events and improved oxygenation. Mean AHI was reduced
from 71.9 ± 30.3 to 8.39 ± 5.15 (P= 0.000). Whereas CPAP
signiﬁcantly reduced the obstructive apnea index (OAI) from
29.50 ± 22.30 to 4.86 ± 3.6 (P= 0.000) (Fig. 1) and the cen-
tral apnea index from 12.8 ± 6.67 to 3.1 ± 2.86 (P= 0.000),
the response to central events was variable (ranged from20% to 100%) (Fig. 2). Average (84.36 ± 6.76 vs. 90.37
± 6.27, P= 0.000) and minimum (58.9 ± 17.5 vs. 79.45
± 9.54, P= 0.000) oxygen saturation were signiﬁcantly
increased with a signiﬁcant reduction in T90 (60.3 ± 47.9 vs.
7.75 ± 11.9, P= 0.000). Arousal index was signiﬁcantly
decreased from 33.98 ± 9.66 to 8.5 ± 6.16 (P= 0.000). Also
CPAP signiﬁcantly increased the slowest heart rate in the titra-
tion night compared to the diagnostic study (49.5 ± 9.01 vs.
37.08 ± 13.8, P= 0.000) (Table 2).
Overall results, 25 (67.6%) of the combined group had suc-
cessful titration with AHI < 5. Among the combined group,
Female patients showed better response to CPAP than males
(88.9% vs. 60.7%, P= 0.019). Patients with successful initial
CPAP titration had a signiﬁcantly higher baseline total AHI,
CAI, REM AHI than those who failed titration (Table 3).
Discussion
Obstructive sleep apnea syndrome is a common sleep related
breathing disorder [14]. Many patients with OSAS show at
Figure 2 The response of central apnea index (CAI) to CPAP in
patients with combined sleep apnea syndrome. CPAP signiﬁcantly
reduced the CAI from 12.8± 6.67 to 3.1 ± 2.86 (P= 0.000).
Note (arrows) the wide variability of response of CAI (varies from
20% to 100%).
676 S. Farghaly, A. Thabetleast a minor proportion of coexisting central disturbances
[15]. That may be likely due to the overlapping of mechanisms
causing these disturbances. Obstructive apneas, probably
through intermittent hypoxia, can increase the ventilatory
response to subsequent apneas and produce central apneas
[16]. Stimulation of the mechanoreceptors of the upper airway
when by obstructive efforts may favor the occurrence of cen-
tral events through their action on the central drive to breathe
[17]. Ventilatory instability (an important pathophysiological
disturbance found in obstructive apnea patients) which leadsTable 2 Polysomnographic parameters of the combined group (n=
Variable Baseline (n= 37)s
Mean ± SD
Sleep parameters
TST (h) 4.56 ± 0.07
Sleep eﬃciency (%) 88.39 ± 4.9
Stage 1 (%) 26.4 ± 12.9
Stage 2 (%) 50.6 ± 19.5
Stage 3 (%) 8.14 ± 13.2
REM (%) 9.11 ± 15.8
Respiratory parameters
AHI (event/h) 71.9 ± 30.3
NREM AHI 72.7 ± 30.7
REM AHI 50.36 ± 29.8
OAI 29.50 ± 22.30
Hypopnea index 12.5 ± 10.4
CAI 12.8 ± 6.67
DI (event/h) 54.48 ± 27.19
Average O2 (%) 84.36 ± 6.76
Minimum O2 (%) 58.9 ± 17.5
T90 (min) 60.3 ± 47.9
Arousal index (event/h) 33.98 ± 9.66
Cardiovascular parameters
Fastest heart rate 101.1 ± 19.6
Slowest heart rate 37.08 ± 13.8
TST, total sleep time; AHI, apnea hypopnea index; OAI, obstructive a
NREM, non-rapid eye movement; DI, desaturation index; T90, time spe
* Signiﬁcant.to pharyngeal obstruction may also increase the ventilatory
response to arousal and drives Pa CO2 below the apnea
threshold during subsequent sleep causing central apnea [18].
In heart failure, there is evidence for an overnight shift in
predominance of obstructive apneas to central apneas [19].
Although CPAP was considered the standard treatment of
OSAS, there was little evidence in its role in patients with
coexisting central and obstructive events.
Thus we carried out this study to evaluate the immediate
effect of CPAP on patients with coexisting obstructive and
central sleep apnea without congestive heart failure. On its
effect on sleep variables, similar to previous studies [20–22]
carried out on OSAS patients, it signiﬁcantly improved all
sleep variables. Light sleep (stage 1 and stage 2) (P< 0.001)
percent was signiﬁcantly decreased with a signiﬁcant increase
in both deep sleep (i.e. stage 3) and REM stage as a % of total
sleep time (P< 0.001). On the other hand, Lofaso and
coworkers [23] found an increase in slow-wave (71 ± 86 vs.
102 ± 149 min) but not REM sleep on APAP and Randerath
et al. [24] found an increase in REM sleep but no change in
slow-wave sleep compared to baseline. In heart failure patients
with coexisting obstructive and Cheyne stoke breathing,
Randerath et al. [25] reported no immediate improvement on
sleep quality on CPAP but only after 3 months of treatment
with a signiﬁcant decrease in stage 1 and 2 (P< 0.01) and
increase in stage 3 (P< 0.01).
The ﬁndings that CPAP signiﬁcantly reduced all apnea
events, arousal and improved oxygenation in our combined
group were comparable with previous studies. In patients with
congestive heart failure, Kasai et al. [26] and Randerath et al.
[25] noted that a signiﬁcant reduction of AHI is in the titration37).
CPAP (n= 37) P-value
Mean ± SD
4.58 ± 0.94 0.345
91.38 ± 4.9 0.016*
18.5 ± 21.85 0.001*
48.66 ± 18.76 0.024*
13.12 ± 12.7 0.014*
13.11 ± 12.85 0.015*
8.39 ± 5.15 0.000*
7.45 ± 6.94 0.000*
6.34 ± 7.34 0.000*
4.86 ± 3.6 0.000*
1.1 ± 0.93 0.000*
3.1 ± 2.86 0.000*
7.08 ± 4.8 0.000*
90.37 ± 6.27 0.000*
79.45 ± 9.54 0.000*
7.75 ± 11.9 0.000*
8.5 ± 6.16 0.000*
103.1 ± 17.27 0.362
49.5 ± 9.01 0.000*
pnea index; CAI, central apnea index; REM, rapid eye movement;
nt below 90% in minutes.
Table 3 Potential predictors of successful initial CPAP titration in the combined group (n= 37).
Variable Successful titration Unsuccessful titration P-value
(N= 25) (N= 12)
Gender %
Male 17 (68.2%) 11 (39.3%) 0.019*
Female 8 (88.9%) 1 (8.3%)
BMI (mean ± SD) 41.34 ± 7.86 43.12 ± 8.32 0.509
ESS (mean ± SD) 10.21 ± 2.6 11.72 ± 2.9 0.105
Baseline AHI (mean ± SD) 62.01 ± 22.56 92.9 ± 22.2 0.000*
Baseline CAI (mean ± SD) 9.9 ± 2.45 15 ± 8.76 0.020*
Baseline NREM AHI (mean ± SD) 73.48 ± 23.1 82.9 ± 23.9 0.075
Baseline REM AHI (mean ± SD) 24.8 ± 14.74 81.48 ± 4.6 0.000*
Data expressed as number (%) or mean ± SD (standard deviation).
ESS, Epworth sleepiness scale; BMI, body mass index; AHI, apnea hypopnea index; CAI, central apnea index; NREM, non-rapid eye
movement; REM, rapid eye movement.
* Signiﬁcant.
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nal CPAP was applied for one night, despite a signiﬁcant
improvement in total AHI and oxygen saturation, central
AHI was reduced on CPAP by about 50%. The better results
reported in this study (reduction of central AHI by 80%)
might be due to that the previous studies evaluate patients with
predominantly central apnea with exclusion of those with
obstructive AHI > 10/h. Furthermore, all hypopneas were
scored as obstructive events as we could not differentiate
between central and obstructive hypopneas and thus the possi-
bility of under estimation of central events in our cases.
Interestingly, as in previous studies, [28,30] we observed that
a reduction of central events was variable (varies from 20%
to 100%). It was supposed that at the time CPAP caused
immediate and complete suppression of obstructive sleep
apnea in patients with [31] and without [32] CHF, its effects
on CSA were gradual and time dependent. Studies applying
gradual CPAP titration protocol and treatment for a period
of 2–12 weeks showed a further improvement of central events
by 50–65% than the ﬁrst night [33,34,28]. As it was postulated
that that breathing stability rather than upper airway collapsi-
bility distinguishes patients with a combination of obstructive
and central events from those with pure OSA, those patients
were expected to take a period to adapt to CPAP [35]. It had
been demonstrated that treatment of CSA with CPAP for a
period of 2 weeks or longer stabilized the ventilatory control
system by increasing nocturnal transcutaneous PCO2, [6] total
body oxygen stores [36] and reducing ventilatory drive [34]. We
hypothesized that central apneas induced by obstructive events
following arousals or induced by negative mechanoreceptor
stimulation could disappear after correction of obstruction
by CPAP. The different mechanisms of the pathogenesis of
patients with combined obstructive and central events led to
heterogeneous response to CPAP. Those patients with patho-
genesis other than ventilatory instability could show immedi-
ate improvement on CPAP.
Interestingly, female patients in our study showed a better
response to CPAP than males. Generally, men had less stable
sleep architecture with frequent arousals and shorter slow
wave than women which might predispose them to respiratory
control system instability [37] and thus the need for time toshow optimum response to CPAP. Furthermore the small
number of females in our study could make this difference.
A problem in sleep apnea studies is the exact differentiation
between obstructive and central hypopneas. Measurement of
esophageal pressure is the gold standard approach to detect
respiratory effort but is difﬁcult to be applied in that study.
Besides, limitations of this study included the small number
of included patients but that was due to the limited inclusion
criteria in that study to ﬁnd this group of patients and also
the absence of a deﬁnite cause of the presence of central events
in those OSAS patients.
In conclusion, CPAP can be effective in combined obstruc-
tive and central apnea patients without heart failure with
consideration of individual variability. So a trial of CPAP
titration should be considered in every patient with combined
sleep apnea syndrome without heart failure. Further studies
are recommended to evaluate the long term effect of CPAP
in those patients.Conflict of interest
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